- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01060189
Hemostatic Effects of Ulinastatin and Tranexamic Acid in Cardiac Surgery
February 2, 2019 updated by: SHI Jia, Chinese Academy of Medical Sciences, Fuwai Hospital
Hemostatic Effects of Ulinastatin and Tranexamic Acid in Cardiac Surgery With Cardiopulmonary Bypass: A Pilot Study
Antifibrinolytic drugs are used to decrease perioperative bleeding and allogeneic transfusions.
The extensively studied antifibrinolytic drug aprotinin is efficacious but expensive, and has been proved to link to higher risks of serious side effects including renal problems, myocardial events, and strokes in patients undergoing CABG.
After the secession of aprotinin in 2007, a marked increase of blood loss and transfusions in cardiac surgery took place.
An effective and secure hemostatic agent is badly needed.
Ulinastatin, urinary trypsin inhibitor(UTI), is a secreted Kunitz-type protease inhibitor with a wide inhibition spectrum, including plasmin.
Limited studies offered clues to its antifibrinolytic effect.
Tranexamic acid has been applied for years with convinced efficacy and safety.
The objective of the study is to evaluate the hemostatic effect of ulinastatin and tranexamic acid in cardiac surgery.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
426
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100037
- Cardiovascular Institute and Fuwai Hospital, CAMS&PUMC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 68 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Atrial or ventricular septum defect patients requiring cardiac surgery with CPB
- Rheumatic or recessive valvular patients requiring valvular repair or replacement with CPB
- Coronary artery disease patients requiring coronary revascularization surgery with CPB
Exclusion Criteria:
- Non-primary cardiac surgery
- Definite liver or renal dysfunction
- Disorder in coagulation function
- Allergy
- Pregnancy or lactation
- Disabled in spirit or law
- Fatal conditions such as tumour
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ulinastatin
1,000,000 units of ulinastatin in 50ml solution before skin incision; 50ml saline solution after neutralization
|
|
Experimental: Tranexamic Acid
15mg/kg tranexamic acid in 50ml solution before skin incision; 15mg/kg tranexamic acid in 50ml solution after neutralization
|
|
Placebo Comparator: Placebo
50ml saline solution before skin incision; 50ml saline solution after neutralization
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Postoperative blood loss
Time Frame: Postoperatively
|
Defined as the total volume of chest drainage postoperatively
|
Postoperatively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of reexploration for bleeding
Time Frame: Postoperatively
|
Postoperatively
|
|
Rate of major bleeding
Time Frame: Perioperatively
|
Major bleeding is defined according to the CURE study
|
Perioperatively
|
Transfusion of allogeneic erythrocytes
Time Frame: Perioperatively
|
Rate of exposure and volume of allogeneic erythrocytes transfused
|
Perioperatively
|
Transfusion of fresh frozen plasma (FFP)
Time Frame: Perioperatively
|
Rate of exposure and volume of FFP transfused
|
Perioperatively
|
Transfusion of allogeneic platelets
Time Frame: Perioperatively
|
Rate of exposure and volume of allogeneic platelets transfused
|
Perioperatively
|
Length of stay in ICU and hospital postoperatively
Time Frame: Postoperatively
|
Postoperatively
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Jia Shi, MD, Cardiovascular Institute and Fuwai Hospital, CAMS&PUMC
- Study Chair: Lihuan Li, MD, Cardiovascular Institute and Fuwai Hospital, CAMS&PUMC
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2008
Primary Completion (Actual)
January 1, 2009
Study Completion (Actual)
January 1, 2019
Study Registration Dates
First Submitted
January 28, 2010
First Submitted That Met QC Criteria
February 1, 2010
First Posted (Estimate)
February 2, 2010
Study Record Updates
Last Update Posted (Actual)
February 5, 2019
Last Update Submitted That Met QC Criteria
February 2, 2019
Last Verified
February 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UTI Pilot Study
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemostasis
-
Biom'Up France SASWithdrawn
-
Biom'Up France SASCompletedHemostasisGermany, France, Austria
-
Emory UniversityCompleted
-
Biom'Up France SASTerminatedHemostasisGermany, France, Austria
-
Instituto Grifols, S.A.CompletedHemostasisUnited States
-
Kantonsspital GraubündenCompleted
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCompletedSurgical HemostasisChina
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho Biotech Clinical Affairs, L.L.C.Terminated
-
Five Liters, Inc.Northwell Health; The Feinstein Institutes for Medical ResearchRecruitingHemostasis | Blood BiomarkersUnited States
Clinical Trials on Tranexamic Acid
-
Icahn School of Medicine at Mount SinaiRecruiting
-
University of LiegeCompletedArthroplasty Complications | Hemorrhage Postoperative | Total Blood LossBelgium
-
London School of Hygiene and Tropical MedicineCompleted
-
Samsung Medical CenterUnknownBleeding | Transfusion Related ComplicationKorea, Republic of
-
Assiut UniversityCompleted
-
Ain Shams UniversityCompleted
-
Aswan University HospitalCompletedCesarean Section ComplicationsEgypt
-
Thammasat UniversityCompleted
-
Ferring PharmaceuticalsCompleted
-
London School of Hygiene and Tropical MedicineRawalpindi Medical CollegeCompletedPregnancy, High RiskPakistan, Zambia